BioSpace News Archive

BD, a leading global medical technology company, announced that it will host a live webcast of its Annual Meeting of Shareholders on Tuesday, January 28, 2020, at 1 p.m..

A collection of six cybersecurity vulnerabilities has been discovered in a range of GE Healthcare devices popular in hospitals, the US Department of Homeland Security’s Cybersecurity and Infrastructure Security Agency (CISA) disclosed today

Nationally renowned cardiovascular surgeons Marc Sakwa, M.D. and Jeffrey Altshuler, M.D. are bringing their leadership, surgical advancements and world-class expertise in minimally invasive heart surgery for complex heart procedures to MemorialCare Heart & Vascular Institute

PharmaForce International (PFI) recently completed a study that benchmarks the leading Immunology sales and marketing organizations in the United States.

Today, the U.S. Food and Drug Administration is issuing a safety communication informing health care providers, facilities and patients about cybersecurity vulnerabilities identified for certain GE Healthcare Clinical Information Central Stations and Telemetry Servers.

eHealth, Inc. (NASDAQ: EHTH), a leading private online health insurance exchange in the United States, today announced preliminary, unaudited financial results and select operating metrics for the fourth quarter and fiscal year ended December 31, 2019.

Intuitive (the “Company”) (Nasdaq: ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced financial results for the quarter ended December 31, 2019.

Leidos (NYSE:LDOS), a FORTUNE® 500 science and technology leader, announced today that Michael Jackman has been named the Leidos Health Group’s chief operating officer (COO).

The National Organization for Rare Disorders (NORD)®, the Foundation for Rare Blood Diseases (SZB) and the pyruvate kinase deficiency community together made history on September 20, 2019 with patients and families sharing their experiences directly with the US Food and Drug Administration (FDA) and other key stakeholders, and first-of-its-kind testimony from the heavily affected Amish community of Belleville, Pennsylvania.

Epizyme, Inc., a biopharmaceutical company developing novel epigenetic therapies, today announced that the U.S. Food and Drug Administration has granted accelerated approval of TAZVERIK™ for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection, based on overall response rate and duration of response in a Phase 2 clinical trial.